191 related articles for article (PubMed ID: 11916236)
1. Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer.
Lee AV; Cui X; Oesterreich S
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4429s-4435s; discussion 4411s-4412s. PubMed ID: 11916236
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
Kurokawa H; Arteaga CL
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
[TBL] [Abstract][Full Text] [Related]
3. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
Massarweh S; Schiff R
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S15-24. PubMed ID: 17259554
[TBL] [Abstract][Full Text] [Related]
4. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities.
Massarweh S; Schiff R
Clin Cancer Res; 2007 Apr; 13(7):1950-4. PubMed ID: 17404074
[TBL] [Abstract][Full Text] [Related]
5. Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations.
Gururaj AE; Rayala SK; Vadlamudi RK; Kumar R
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1001s-1007s. PubMed ID: 16467116
[TBL] [Abstract][Full Text] [Related]
6. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
Cui X; Schiff R; Arpino G; Osborne CK; Lee AV
J Clin Oncol; 2005 Oct; 23(30):7721-35. PubMed ID: 16234531
[TBL] [Abstract][Full Text] [Related]
7. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling.
Clarke R; Liu MC; Bouker KB; Gu Z; Lee RY; Zhu Y; Skaar TC; Gomez B; O'Brien K; Wang Y; Hilakivi-Clarke LA
Oncogene; 2003 Oct; 22(47):7316-39. PubMed ID: 14576841
[TBL] [Abstract][Full Text] [Related]
8. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators.
Schiff R; Massarweh SA; Shou J; Bharwani L; Arpino G; Rimawi M; Osborne CK
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():10-20. PubMed ID: 16273359
[TBL] [Abstract][Full Text] [Related]
9. Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer.
Johnston SR; Head J; Pancholi S; Detre S; Martin LA; Smith IE; Dowsett M
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):524S-32S. PubMed ID: 12538510
[TBL] [Abstract][Full Text] [Related]
10. Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer.
Kim HJ; Cui X; Hilsenbeck SG; Lee AV
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1013s-1018s. PubMed ID: 16467118
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor: current understanding of its activation and modulation.
Osborne CK; Schiff R; Fuqua SA; Shou J
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4338s-4342s; discussion 4411s-4412s. PubMed ID: 11916222
[TBL] [Abstract][Full Text] [Related]
12. Role of IRS-1 signaling in insulin-induced modulation of estrogen receptors in breast cancer cells.
Andò S; Panno ML; Salerno M; Sisci D; Mauro L; Lanzino M; Surmacz E
Biochem Biophys Res Commun; 1998 Dec; 253(2):315-9. PubMed ID: 9878535
[TBL] [Abstract][Full Text] [Related]
13. Membrane-initiated steroid signaling action of estrogen and breast cancer.
Song RX
Semin Reprod Med; 2007 May; 25(3):187-97. PubMed ID: 17447208
[TBL] [Abstract][Full Text] [Related]
14. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J; Sommer A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
[TBL] [Abstract][Full Text] [Related]
15. Cross-talk between estrogen receptors and insulin-like growth factor-I receptor in the brain: cellular and molecular mechanisms.
Mendez P; Wandosell F; Garcia-Segura LM
Front Neuroendocrinol; 2006 Dec; 27(4):391-403. PubMed ID: 17049974
[TBL] [Abstract][Full Text] [Related]
16. Biologic basis of sequential and combination therapies for hormone-responsive breast cancer.
Pietras RJ
Oncologist; 2006; 11(7):704-17. PubMed ID: 16880230
[TBL] [Abstract][Full Text] [Related]
17. [Hormone resistance and its modulation in breast cancer].
Kahán Z; Thurzó L
Orv Hetil; 2005 Apr; 146(16):731-7. PubMed ID: 15889669
[TBL] [Abstract][Full Text] [Related]
18. New strategies in estrogen receptor-positive breast cancer.
Johnston SR
Clin Cancer Res; 2010 Apr; 16(7):1979-87. PubMed ID: 20332324
[TBL] [Abstract][Full Text] [Related]
19. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance.
Lewis JS; Jordan VC
Mutat Res; 2005 Dec; 591(1-2):247-63. PubMed ID: 16083919
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.
Schiff R; Massarweh S; Shou J; Osborne CK
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):447S-54S. PubMed ID: 12538499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
